Summary & Overview
HCPCS J0570: Buprenorphine Implant, 74.2 mg
HCPCS Level II code J0570 denotes a 74.2 mg buprenorphine subdermal implant used as a long-acting treatment option for opioid use disorder. Its designation as an HCPCS Level II code identifies it as a billable drug or biological supplied and administered in clinical settings. Nationally, long-acting buprenorphine implants are significant for expanding medication-assisted treatment options and supporting continuity of care for patients with opioid dependence.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage and reimbursement considerations across major commercial and public payers, common billing and service settings where this implant is used, and clinical context about its role in medication-assisted treatment. The publication also summarizes relevant benchmarks and potential policy updates that affect billing, prior authorization, and site-of-service considerations.
This summary provides clinicians, billing professionals, and policy analysts with a concise reference to the code’s clinical purpose, expected service delivery settings, and the payer landscape relevant to national billing practices.
Billing Code Overview
HCPCS Level II code J0570 represents a buprenorphine implant, 74.2 mg. This code describes a long-acting subdermal implant formulation of buprenorphine used in the treatment of opioid use disorder.
Service Type: Medication implant / long-acting opioid agonist therapy
Typical Site of Service: Outpatient procedure setting, ambulatory infusion clinic, or behavioral health clinic with capability for minor implant procedures
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with opioid use disorder presents to an ambulatory surgical center for placement of a subdermal J0570 buprenorphine implant (74.2 mg) as part of long-acting medication-assisted treatment. The patient has completed pre-procedure assessment including substance use history, medication review, localized skin exam of the upper inner arm, consent, and brief counseling. On the day of service a clinician (typically an addiction medicine physician, board-certified psychiatrist, or a trained family medicine physician) administers local anesthesia, creates a small subdermal pocket in the upper inner arm, inserts the J0570 implant(s) per manufacturer technique, and closes the insertion site with adhesive strips or a single suture if needed. Post-procedure care includes observation for immediate complications (bleeding, vasovagal reaction, allergic response), wound care instructions, and scheduling follow-up for implant check and removal (typically after 6 months) or management of adverse effects. Typical site of service is an ambulatory surgical center, outpatient clinic, or physician office procedure room equipped for minor surgical procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; not recommended for reporting specific situations |